Professional Documents
Culture Documents
Thymox EPO
Thymox EPO
The botanical species is certified by DNA barcoding analysis. No harmful solvent is used in the
manufacturing process, which is entirely made in Italy, with full traceability from the field to the
final packaging and a production chain that is checked at every stage. The quantification of bioactive
compounds is accurately performed by sophisticated analytical methods and in compliance with EU
legislation on food and food supplements.
Its efficacy is based on preclinical evidence, providing its double effect as an anti-inflammatory and
expectorant agent, which makes Thymox-EPO suitable for respiratory tract inflammations, asthma,
dry and productive cough.
Activity
Thymox-EPO has been tested on 3D in vitro cellular model, which faithfully reproduces the
physiological condition. It was demonstrated that Thymox-EPO has a good expectorant and anti-
inflammatory activity.
The respiratory tract has epithelial cells that are characterized by cilia on the surface. Expectoration
consists in the movement of mucus through the respiratory tract thanks to the efficient beating of the
cilia a Ca2+-mediated mechanism.
Thymox was shown to increase extracellular cAMP levels; it increases Ca 2+influx while decreasing
extracellular Ca2+level; therefore, enhancing ciliary beating frequency. By increasing the frequency
of beating, Thymox- EPO helps mucus clearance (expectoration).
The recommended daily dosage is 10 g drug with 0.03% phenol, calculated as thymol, corresponding
to 1 g of Thymox-EPO (Thyme dry extract 0.3%).